Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation
NCT01637597 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12
Last updated 2016-07-21
Summary
This is an exploratory study in patients with locally advanced or metastatic Non-small cell lung cancer. Patients who are eligible to apply for Extended Access Program of crizotinib must have ALK translocation detected by RT-PCR, IHC or FISH analyses methods.
Conditions
- Non-small Cell Lung Cancer(NSCLC)
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Principal Investigators
-
James Chih-Hsin Yang, MD, PhD · National Taiwan University Hospital
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2016-12-31
- Completion
- 2017-03-31
Countries
- Taiwan
Study Locations
More Related Trials
-
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT06254599 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
NCT01300429 ·Status: COMPLETED
-
Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients
NCT05792644 ·Status: COMPLETED ·Phase: NA
-
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
NCT02075840 ·Status: COMPLETED ·Phase: PHASE3
-
Primary Resistance Mechanisms of ALK TKIs
NCT07045610 ·Status: NOT_YET_RECRUITING
-
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
NCT01639001 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
NCT02271139 ·Status: NO_LONGER_AVAILABLE
-
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
NCT01945021 ·Status: COMPLETED ·Phase: PHASE2
-
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
NCT01121588 ·Status: TERMINATED ·Phase: PHASE1
-
Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer
NCT03647111 ·Status: RECRUITING
-
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
NCT03535740 ·Status: COMPLETED ·Phase: PHASE2
-
Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)
NCT02499614 ·Status: UNKNOWN ·Phase: PHASE2
-
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
NCT03672643 ·Status: TERMINATED ·Phase: PHASE4
-
A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.
NCT01955681 ·Status: COMPLETED
-
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
NCT02679170 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer
NCT03155009 ·Status: COMPLETED ·Phase: PHASE2
-
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
NCT05014464 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
NCT06282991 ·Status: COMPLETED
-
An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients
NCT02708667 ·Status: UNKNOWN
-
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
NCT02737501 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02838420 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer
NCT01874678 ·Status: COMPLETED ·Phase: NA
-
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
NCT04111705 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
NCT02094573 ·Status: COMPLETED ·Phase: PHASE2